文献速递中医内科中药与中成药合理使用

消炎利胆片治疗胆汁淤积性肝损伤的药理机制及主要贡献药材

Uncovering the pharmacological mechanism and the main herbal medicine contributing to the efficacy of Xiaoyanlidan Tablet (XYLDT) in treating cholestatic liver injury.
PubMed 文献 · J Ethnopharmacol · 2024-11-28

本研究在ANIT诱导的小鼠胆汁淤积性肝损伤模型中,观察消炎利胆片及其拆方各组方的疗效,并结合临床数据分析与细胞实验验证机制。结果显示消炎利胆片通过改善氧化应激、激活Nrf2相关信号通路减轻肝损伤,其中穿心莲(AH)对疗效贡献最大。

要点

  • 消炎利胆片可减轻ANIT诱导的小鼠胆汁淤积性肝损伤,机制与改善氧化应激及激活Nrf2通路有关。
  • 穿心莲是消炎利胆片中对该模型疗效贡献最重要的药材。
  • 穿心莲内酯和新穿心莲内酯在LPS刺激的RAW264.7细胞中显示抗炎能力,穿心莲内酯促进L-02细胞中Nrf2核转位。

核心结论

  • 消炎利胆片通过改善氧化应激和激活Nrf2相关信号通路缓解ANIT诱导的小鼠胆汁淤积性肝损伤,穿心莲为其中起主要治疗作用的药材。

研究设计与样本

  • 采用ANIT口服诱导小鼠胆汁淤积性肝损伤模型,分别给予各单味药、缺味方和全方,在ANIT给药前后口服,检测血清生化指标和肝脏组织病理学。
  • 结合临床数据分析预测消炎利胆片改善胆汁淤积性肝损伤涉及的分子和信号通路,并用RT-PCR和Western-blot验证。
  • 细胞实验采用LPS刺激的RAW264.7细胞和ARE-荧光素酶转染的L-02细胞评价穿心莲内酯和新穿心莲内酯的抗炎及Nrf2激活能力。

主要发现

  • 血清生化指标和肝脏组织学观察证实消炎利胆片减轻ANIT诱导的胆汁淤积性肝损伤。
  • 消炎利胆片降低ROS水平和MDA含量,升高GSH含量,并提高Nrf2入核水平及Nqo1、Gclc、Gclm的mRNA表达。
  • 穿心莲被证明对消炎利胆片治疗胆汁淤积性肝损伤的疗效最为关键。
  • 穿心莲内酯和新穿心莲内酯在LPS刺激的RAW264.7细胞中具有明显抗炎能力,穿心莲内酯促进ARE-荧光素酶转染L-02细胞中Nrf2的核转位激活。

临床怎么用

  • 该研究为消炎利胆片用于胆汁淤积性肝损伤相关适应症(如中医肝胆湿热所致的胁痛、口苦)提供了氧化应激和Nrf2通路层面的机制解释。
  • 结果提示穿心莲是消炎利胆片疗效的主要贡献药材,其活性成分穿心莲内酯和新穿心莲内酯具有抗炎及激活Nrf2的体外活性。

局限性

  • 研究为动物模型和细胞实验,临床数据仅用于预测分析,尚需进一步临床研究验证。
  • 原文未报告样本量、具体剂量、P值等详细统计信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Xiaoyanlidan Tablet (XYLDT) is a Chinese patent medicine consisted of three traditional Chinese medicines (TCMs) including Andrographis Herba (AH), Linearstripe Rabdosia Herba (LRH) and Picrasmae Ramulus et Folium (PRF). In Chinese traditional medicine theory, XYLDT has the "heat-clearing, dampness-dispelling and gallbladder function promoting" properties, and was widely used in the clinic for decades to treat pain in the subcostal region or bitter taste in the mouth, which were induced by liver-gallbladder dampness-heat. Meanwhile, it was also used for the therapy of acute cholecystitis and cholangitis. AIM OF THE STUDY: To explore the mechanism of XYLDT in alleviating the alpha-naphthylisothiocyanate (ANIT)-induced cholestatic liver injury (CLI), and to find out which TCM consisted in XYLDT contributed the most to the therapeutic efficacy of XYLDT. METHODS: ANIT was orally given to mice to induce CLI in vivo. Each TCM in XYLDT alone, XYLDT-without one TCM or XYLDT was orally given to mice before or after ANIT administration. Serum biochemical indicators were measured by using commercial kits. Liver histopathology was observed. Clinical data analysis was used to predict molecules and signal pathways involved in the XYLDT-provided improvement on CLI, which was further verified by using RT-PCR and Western-blot assay. RESULTS: The alleviation of XYLDT on ANIT-induced CLI was proved by the data of serum biochemical indicators and liver histological observation. Results from clinical data analysis indicated that XYLDT improved CLI via improving mitochondrial function, oxidative phosphorylation, oxidative stress. XYLDT reduced the ROS level, MDA content, and increased GSH content. Meanwhile XYLDT improved the level of Nrf2 into the nucleus and mRNA expression of Nqo1, Gclc, Gclm. Andrographis Herba was proved to be the most crucial for the XYLDT-provided therapeutic efficacy on CLI. Moreover, andrographolide and neoandrographolide, two main active compounds in Andrographis Herba, had the apparent anti-inflammatory ability in LPS-stimulated RAW264.7 cells. Andrographolide also promoted nuclear translocation activation of Nrf2 in antioxidant response elements (ARE)-luciferin transfected L-02 cells. CONCLUSION: XYLDT alleviated the ANIT-induced CLI via improving oxidative stress and activated Nrf2-related signaling pathways. Andrographis Herba was important for the XYLDT-provided alleviation on CLI.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wu Z, Shi J, Zhang Y, et al. Uncovering the pharmacological mechanism and the main herbal medicine contributing to the efficacy of Xiaoyanlidan Tablet (XYLDT) in treating cholestatic liver injury. J Ethnopharmacol. 2024. PMID: 39613007. doi:10.1016/j.jep.2024.119163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。